Leonard Schleifer was bornon 1953 in Tarrytown, New York, United States, is CEO and Founder, Regeneron Pharmaceuticals. Leonard Schleifer is #1747 in List Billionaires People In The World. Leonard Schleifer cofounded drugmaker Regeneron in 1988. He remains CEO of the Tarrytown, New York company, which has been looking for a follow-up to Eylea, a treatment for macular degeneration with more than $5 billion in sales. Their big hope, cholesterol drug Praluent, has had disappointing sales and faces a patent infringement case from rival Amgen. Regeneron is now betting on a treatment for atopic dermatitis to be a big hit. Schleifer, who has most of his fortune tied up in Regeneron, grew up in Queens. He was the son of a sweater manufacturer who attended Cornell on scholarship and dreamed of a medical career but had to return to the family business. Schleifer followed his father's footsteps to Cornell and then got an M.D.-PhD degree at the University of Virginia, training with future Nobel Laureate Alfred Gilman. Regeneron now sponsors the Science Talent Search competition for high school students. It was previously run by Westinghouse, then, more recently, Intel. Schleifer competed as a teenager.
According to the "annual collaborative report" from Equilar and The New York Times, Schleifer ranked 15th in the May 2015 list of "200 highest-paid CEOs of large publicly traded companies
As CEO Schleifer received a total compensation of $41,965,424 in 2014
" In 2011, Regereron's first successful drug was, Eylea, for age-related macular degeneration
He also recruited George Yancopoulos, a 28-year-old scientist, to be his partner, and in 1988 they founded Regeneron Pharmaceuticals
Schleifer (born 1953) is the founder and chief executive of the biotechnology company Regeneron